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Abstract
Background
Understanding pattern of antimalarials use at large scale helps ensuring appropriate use of
treatments and preventing the spread of resistant parasites. We estimated the proportion of
individuals in community surveys with residual antimalarials in their blood and identified the
factors associated with the presence of the most commonly detected drugs, lumefantrine
and/or desbutyl-lumefantrine (LF/DLF) or sulfadoxine-pyrimethamine (SP).
Methods
A cross-sectional survey was conducted in 2015 in three regions of Tanzania with different
levels of malaria endemicity. Interviews were conducted and blood samples collected
through household surveys for further antimalarial measurements using liquid chromatogra-
phy coupled to tandem mass spectrometry. In addition, diagnosis and treatment availability
was investigated through outlet surveys. Multilevel mixed effects logistic regression models
were used to estimate odds ratios for having LF/DLF or SP in the blood.
Results
Amongst 6391 participants, 12.4% (792/6391) had LF/DLF and 8.0% (510/6391) SP in the
blood. Factors associated with higher odds of detecting LF/DLF in the blood included fever
in the previous two weeks (OR = 2.6, p<0.001), living in districts of higher malaria preva-
lence (OR = 1.5, p<0.001) and living in a ward in which all visited drug stores had artemisi-
nin-based combination therapies in stocks (OR = 2.7, p = 0.020). Participants in older age
groups were less likely to have LF/DLF in the blood (OR = 0.9, p<0.001). Factors associated
with higher odds of having SP in the blood included being pregnant (OR = 4.6, p<0.001), liv-
ing in Mwanza (OR = 3.9, p<0.001 compared to Mbeya), fever in the previous two weeks
(OR = 1.7, p<0.001) and belonging to older age groups (OR = 1.2, p<0.001).
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Conclusion
The most significant predictors identified were expected. History of fever in the past two
weeks and young age were significant predictors of LF/DLF in the blood, which is encourag-
ing. Antimalarial drug pressure was high and hence the use of recommended first-line drugs
in combination with malaria Rapid Diagnostics Tests should be promoted to ensure appro-
priate treatment.
Introduction
Artemisinin-based combination therapies (ACTs) are the most potent weapon in treating fal-
ciparum malaria [1], representing the second highest impact intervention on malaria control
between 2000 and 2015 [2]. In response to the development of parasite resistance to conven-
tional antimalarials such as chloroquine, the World Health Organisation (WHO) recom-
mended ACTs as first-line therapy for uncomplicated malaria in 2006 [3] when the Ministry
of Health and Social Welfare of Tanzania had already recommended artemether-lumefantrine
(Alu) as standard therapy in 2005 [4]. The use of antimalarials as combination therapy is yet
clearly of benefit for the individuals [5], but artemisinin itself is rapidly eliminated while the
“partner drugs” persist in the bloodstream as monotherapy for weeks due to their long half-
lives [6]. Despite its poor efficacy and a high proportion of resistant parasites in Tanzania [7–
9], sulfadoxine-pyrimethamine (SP) is still widely used as self-medication outside of intermit-
tent preventive treatment during pregnancy (IPTp) [10,11]. The antimalarials currently used
in combination with artemisinin derivates in Tanzania as well as sulfadoxine (SD) and pyri-
methamine (PM) have long half-lives [lumefantrine (LF): 3 to 6 days, its active metabolite des-
butyl-lumefantrine (DLF): 5 to 6 days, amodiaquine (AQ): 2.7–5.1 hours; its active metabolite
N-desethyl-amodiaquine (DAQ): 7 to 10 days; quinine (Q): 7 to 21 hours; chloroquine (CQ):
10 to 30 days; mefloquine (MQ): 17 to 24 days; SD: 5 to 7 days; PM: 3 to 4 days)] [12–17]. The
extensive and often inadequate use of these long-acting compounds constitutes a critical factor
contributing to drug pressure [18], which in turn is a potent force selecting resistant parasites
[19,20]. Thus, correct use of antimalarials is now one of the five goals and recommendations
of WHO Global plan for artemisinin resistance containment [1]. Understanding the pattern of
antimalarial drugs usage will help designing specific and targeted interventions aimed at
reducing drug pressure and monitoring the implementation of diagnostic and treatment
policies.
Previous studies have explored the effect of environmental and behavioral factors on popu-
lation drug use. Most of them relied on questionnaires [10,21–23] although there was no indi-
cation that information collected through self-reporting was reliable. With such methodology,
uptake of antimalarials was reported to be low [20,24]. On the other hand, studies conducted
during the CQ or SP eras [19,20,25,26] using biochemical markers in addition to question-
naires showed high prevalence of individuals with detectable drug in urine or blood, although
the tests used had a rather poor sensitivity. Two recent studies using liquid chromatography
coupled to tandem mass spectrometry (LC-MS/MS), a sensitive analytical method, showed
that 52% of the patients upon admission to a health facility (HF) in Cambodia [27] and 74% in
Tanzania [28] had detectable antimalarials in their blood, although all of them stated that they
had not taken any drug in the previous four weeks. These observations indicate frequent
recourse to self-medication and poor reliability of self-reporting when assessing drug use. Our
study first aimed at evaluating the actual state of population drug pressure by estimating the
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proportion of individuals in community surveys with residual antimalarials in their blood, and
then at identifying the factors associated with the presence of LF or SP in the blood.
Methods
A cross-sectional investigation including household-based and drug outlet-based surveys was
conducted concurrently. Detailed study setting, population and sampling have been described
elsewhere [29] and can be summarized as follows.
Study setting and population
Surveys were conducted in three regions of Tanzania with different levels of malaria endemic-
ity, i.e moderately high for Mtwara and Mwanza (17.4% and 16.1% respectively) and low for
Mbeya (2.3%) [30]. Our study took place from May to August 2015 following the rainy season.
In this country where the population is predominantly rural, over 95% of inhabitants of main-
land Tanzania are at risk of malaria [31]. Alu is the first line recommended therapy in Tanza-
nia and is free of charge in public health facilities (HFs) for under five children, pregnant
women, elderly and those who cannot afford to pay [30]. Although no-longer indicated for
malaria case management, SP is still widely available both in the private and public sector,
according to recent outlet surveys [32].
Study sampling and data collection
Tanzania has four different administrative levels: regions, divisions, districts and wards (which
include five to seven villages). In each region, one urban and two rural districts were selected.
Three wards per district, four streets or sub villages per ward, 20 household per sub village/
street and up to six individuals per household were randomly selected. Wards were randomly
selected proportionally to their population size amongst all the wards included in the selected
districts, using an adapted version of sample command in R (version 3.4.0), using population
as probability weights. The same methodology was applied for the villages and street selection.
The questionnaire in Swahili was divided into 3 parts: i) household-related questions on
indoor residual spraying (IRS), time to the closest HF and closest drug retailer; ii) demo-
graphic information, use of bed nets, pregnancy, history of fever in the previous two weeks
and history of antimalarial use in the previous month; iii) information on health seeking
behaviour. The drug outlet surveys included all HFs (small district hospitals, public and private
health centres, dispensaries) and drug stores [pharmacies, registered accredited drug dispens-
ing outlets (ADDOs) and non-registered drug retailers, general stores and kiosks] surrounding
the selected villages. Diagnostic tools [malaria Rapid Diagnostics Tests (mRDTs) and micro-
scope] and antimalarials in stocks at the time of the visit were recorded.
Laboratory procedures
Capillary blood was collected from all participants of the household surveys for mRDTs analy-
sis (ParaHIT-f test, Span diagnostic Ltd, Surat, India, detecting HRP-2 antigens) and applied
on filter paper cards (FTA DMPK-B cards, Whatman, GE Healthcare). These were able to dry
at room temperature for at least two hours before being placed in a specific bag with desiccant
and stored in a -10˚C freezer at the end of the day at study site. Samples were then transferred
to a -80˚C freezer at the Ifakara Health Institute within one month and finally at the University
Hospital of Lausanne, Switzerland. The analysis of seven antimalarials and two active metabo-
lites (LF, DLF, SD, PM, Q, MQ, CQ, AQ, DAQ) was further performed by LC-MS/MS in the
dried blood spots (DBS) samples. The analytical method achieved good performances in terms
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of trueness (-12.1 to +11.1%) and precision (1.4 to 15.0%). All analytes were stable in DBS kept
for 24h at room temperature and at 37˚C [33,34]. They were also found to be stable when
mimicking the study storage and transportation conditions (unpublished data).
Data management and statistical analysis
The Open Data Kit collection tool (ODK) programmed on electronic tablets was used to col-
lect the data and record Global Positioning System coordinates of each household and drug
outlet visited. Data was stored on the ODK Aggregate data repository at the end of each survey
day. R (version 3.4.0) was used for data cleaning and management and to produce logistic
regressions as well as forest plots using the lme4 and sjPlot packages.
Variable definitions. Individuals were considered having an antimalarial in the blood if
the concentrations measured in their corresponding DBS sample were equal or higher than
the lower limit of quantification (LOQ) [34]. Age was categorized as presented in Tables 1 and
2, based on the age distribution of the sampled population. Mean malaria endemicity was clas-
sified according to the most recent epidemiological profile of mainland Tanzania from the last
Malaria Indicator Survey [35]. The following variables were used as binary variables: history of
fever (in the two weeks prior to the survey), mRDT result (performed on the day of the survey),
bednet use (the previous night), IRS (the previous year), pregnancy (at the time of the survey)
and living in an urban or rural district. Participants were asked to estimate the time to reach
the closest HF or drug store (DS) using the mode of transport they would normally use. Out-
lets were considered to have mRDTs and antimalarials in stock if at least one non-expired test
and respectively one complete non-expired treatment of any antimalarial for any age/weight
group was observed.
Multilevel mixed effects logistic regression analysis. The presence of lumefantrine and/
or desbutyl-lumefantrine (LF/DLF) and the presence of sulfadoxine and/or pyrimethamine
(SP) were selected as outcome variables, as they were the antimalarials most frequently
detected in the sampled population. LF and DLF were grouped as a unique outcome because
the presence of either the parent compound (LF), the metabolite (DLF) or both of them con-
currently in the blood indicates a recent intake of LF. A bivariate analysis was first performed
to select variables based on the p-value of the log-likelihood ratio tests, with a cut-off of 0.2
[36]. This approach helps to first identify the most relevant variables to be included in a more
complex model by minimizing the risk of selecting confounding factors. Multilevel mixed
effects logistic regression models were then performed by a backward step-by-step procedure.
Independent variables and their interactions were retained when significance level was less or
equal to 0.05 and if they showed a model fit improvement [i.e. reduction in the Akaike Infor-
mation Criteria (AIC) value of the mode]. According to sampling design, regions, district and
wards were included as nested random effects.
Ethical approval
This epidemiological study received approval from the Swiss Ethics Committees on research
involving humans and from two responsible local authorities (Institutional review board of the
Ifakara Research Institute and the National Institute for Medical Research in Tanzania). Inter-
views were conducted and capillary blood samples were obtained after receiving written
informed consent in Kiswahili by the participants or their responsible caretaker.
Results
In total, 6485 participants were included in the household surveys but 94 were excluded of the
present analysis because their DBS sample was not found or mislabelled. On average, 237
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Table 1. Sample characteristics of included individuals and strength of association between variables and presence of LF/DLF in the blood.
Total participants Participants with LF/DLF in the blood
N (%) N (%) 95% CI Bivariate analysis Multivariate analysis
ORs p-value ORs p-value
Total 6391 (100.0) 792 (12.4) 11.7–13.1 - - - -
Sex
Male 2802 (43.8) 350 (12.5) 11.5–13.5 0.97 0.673 - -
Female 3573 (55.9) 441 (12.3) 11.4–13.2
Missing 16 (0.3) - -
Age
0–4 years 1135 (17.8) 157 (13.8) 12.1–15.5 0.92 <0.001 0.92 <0.001
5–9 years 996(15.6) 170 (17.1) 15.1–19.0
10–14 years 765 (12.0) 111 (14.5) 12.4–16.6
15–24 years 973 (15.2) 83 (8.5) 7.1–10.0
25–44 years 1422 (22.2) 129 (9.1) 7.8–10.3
45–59 years 552 (8.6) 79 (14.3) 11.9–16.8
60–100 years 445 (7.0) 49 (11.0) 8.6–13.5
Missing 103 (1.6) - -
Pregnant
Yes 104 (1.6) 10 (9.6) 4.8–14.4 0.71 0.297 - -
No 1569 (24.6) 135 (8.6) 7.4–9.8
Not applicable 4718 (73.8) - -
Had a fever in the previous 2 weeks
Yes 1021 (16.0) 247 (24.2) 22.0–26.4 2.70 <0.001 2.62 <0.001
No 5364 (83.9) 544 (10.1) 9.5–10.8
Missing 6 (0.1) - -
mRDT result
Positive 1117 (17.5) 222 (19.9) 17.9–21.8 1.25 0.023 1.14 0.183
Negative 5272 (82.5) 570 (10.8) 10.1–11.5
Missing 2 (0.0) - -
Net use
Yes 4180 (65.4) 555 (13.3) 12.5–14.2 1.36 <0.001 1.30 0.004
No 2211 (34.6) 238 (10.8) 9.7–11.8
Missing 0 (0.0) - -
IRS in the previous year
Yes 1073 (16.8) 147 (13.7) 12.0–15.4 0.99 0.802 - -
No 5316 (83.2) 645 (12.1) 11.4–12.9
Missing 2 (0.0) - -
Area
Urban 2185 (34.2) 172 (7.9) 6.9–8.8 1.59 0.359 - -
Rural 4206 (65.8) 620 (14.7) 13.8–15.7
Missing 0 (0.0) - -
Region
Mbeya (reference) 1970 (30.8) 151 (7.7) 6.7–8.6 - - - -
Mwanza 2304 (36.1) 338 (14.7) 13.5–15.9 2.15 0.137 - -
Mtwara 2117 (33.1) 303 (14.3) 13.1–15.6 2.49 0.075 - -
Missing 0 (0.0) - -
PfPR2-10 of the ward
0 < 1% 1421 (22.2) 244 (17.2) 15.5–18.8 0.97 0.655 - -
(Continued)
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Table 1. (Continued)
Total participants Participants with LF/DLF in the blood
N (%) N (%) 95% CI Bivariate analysis Multivariate analysis
ORs p-value ORs p-value
1 - < 5% 0 (0.0) - -
5 - < 10% 1453 (22.7) 202 (13.9) 12.4–15.4
10 - < 50% 2062 (32.3) 183 (8.9) 7.8–9.9
> 50% 1455 (22.8) 163 (11.2) 9.8–12.6
Missing 0 (0.0) - -
PfPR2-10 of the district
0 < 1% 1244 (19.5) 48 (3.9) 3.0–4.8 1.53 0.002 1.52 <0.001
1 - < 5% 0 (0.0) - -
5 - < 10% 1470 (23.0) 138 (9.4) 8.1–10.6
10 - < 50% 2259 (35.3) 343 (15.2) 13.9–16.4
> 50% 1418 (22.2) 263 (18.6) 16.8–20.2
Missing 0 (0.0) - -
Time to the closest HF
<15 min 2134 (33.4) 276 (12.9) 11.7–14.1 0.85 0.011 0.84 0.007
15 min to 1h 3483 (54.5) 430 (12.3) 11.4–13.3
1h to 2h 564 (8.8) 57 (10.1) 8.0–12.2
> 2h 167 (2.6) 26 (15.6) 10.9–20.2
Don’t know 43 (0.7) - -
Time to the closest DS
<15 min 2911 (45.5) 331 (11.4) 10.4–12.3 1.05 0.385 - -
15 min to 1h 2599 (40.7) 354 (13.6) 12.5–14.7
1h to 2h 461 (7.2) 60 (13.0) 10.4–15.6
> 2h 63 (1.0) 9 (14.3) 7.0–21.5
Don’t know 357 (5.6) - -
ACTs in stocks in all the visited HF of the ward
Yes 6391 (100.0) 792 (12.4) 11.7–13.1 - - - -
No 0 (0.0) - -
Missing 0 (0.0) - -
AM in stocks in all the visited HF of the ward
Yes 6391 (100.0) 792 (12.4) 11.7–13.1 - - - -
No 0 (0.0) - -
Missing 0 (0.0) - -
mRDTs in stocks in all the visited HF of the ward
Yes 4986 (78.0) 534 (10.7) 10.0–11.4 0.68 0.139 - -
No 1405 (22.0) 258 (18.4) 16.7–20.1
Missing 0 (0.0) - -
ACTs in stocks in all the visited DS of the ward
Yes 5528 (86.5) 667 (12.1) 11.3–12.8 2.88 0.008 2.69 0.020
No 399 (6.2) 16 (4.0) 2.4–5.6
Missing 464 (7.3) - -
AM in stocks in all the visited DS of the ward
Yes 5694 (89.1) 669 (11.7) 11.0–12.4 2.53 0.039 - -
No 233 (3.6) 14 (6.0) 3.4–8.6
Missing 464 (7.3) - -
mRDTs in stocks in all the visited DS of the ward
(Continued)
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individuals were interviewed in each ward, ranging from 166 to 380. The outlet surveys
included 2 hospitals, 19 health centres, 39 dispensaries, 78 ADDOs, 57 non registered drug
stores, 9 pharmacies and 4 general stores or kiosks.
Site and study participants description
Females were 55.9% (3573/6391) while males were 43.8% (2802/6391). The median age was 17
years and ranged from three months, one of the inclusion criteria, to 100 years. Overall, 4421
participants were sampled in regions of high endemicity (2304 in Mwanza and 2117 in
Mtwara) and 1970 in Mbeya, the region of low endemicity. Majority of the participants lived
in rural districts [65.8% (4206/6391)]. Summary statistics for all assessed variables are shown
in Tables 1 and 2.
Prevalence of antimalarials in the blood of the surveyed population
Antimalarial drugs were present in the blood of 20.8% (1330/6391) (95%CI: 20.0–21.6) of indi-
viduals in total: 53.4% (710/1330) had LF, 14.2% (189/1330) DLF, 20.5% (272/1330) SD, 26.5%
(352/1330) PM, 1.9% (26/1330) Q, 0.6% (8/1330) MQ, 0.2% (3/1330) CQ, 0.1% (2/1330) AQ
and 6.5% (86/1330) DAQ. Additionally, 59.5% (792/1330) of individuals had LF and/or DLF
(107 individuals had both and 685 had one or the other) and 38.3% (510/1330) SP. When con-
sidering parent drug and metabolite or combined treatment as one drug (LF/DLF, AQ/DAQ
and SP), 6.6% (88) of the 1330 participants with residual drug concentrations in the blood had
more than one antimalarial in the blood: 84 individuals had two different drugs, 2 had three
drugs and 2 had five drugs. The proportions of participants with each type of antimalarial in
their blood per region are detailed in Fig 1. In Mtwara, the proportion of individuals with LF/
DLF in their blood [74.1% (303/409)] was significantly higher than in Mwanza [52.5% (338/
644), p<0.001] and Mbeya [54.5% (151/277), p<0.001]. Inversely, the proportion of individu-
als with SP in their blood was significantly higher in Mwanza [43.6% (281/644), p<0.001] and
Mbeya [48.4% (134/277), p<0.001] than in Mtwara [23.2% (95/409)].
Variables associated with the presence of antimalarials
The full list of variables and interaction terms investigated in the multivariate logistic regres-
sion model to assess their association with LF/DLF or SP in the blood are summarized in
Table 3, while the results of the bivariate and multivariate analysis can be found in Tables 1
and 2. In the multivariate analysis, ignoring interaction terms (Fig 2), an increasing age
Table 1. (Continued)
Total participants Participants with LF/DLF in the blood
N (%) N (%) 95% CI Bivariate analysis Multivariate analysis
ORs p-value ORs p-value
Yes 713 (11.2) 56 (7.9) 6.2–9.5 0.73 0.126 - -
No 5217 (81.6) 627 (12.0) 11.3–12.8
Missing 464 (7.3) - -
HF = Health Facility.
DS = Drug Store.
AM = antimalarial drug.
In the bivariate analysis, p-values are based on log-likelihood ratio tests. Variables with more than two categories were considered as ordinal, except for the regions. Net
use was defined as use in the previous night and PfPR2-10 as malaria endemicity.
https://doi.org/10.1371/journal.pone.0202745.t001
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Table 2. Sample characteristics of included individuals and strength of association between variables and presence of SP in the blood.
Total participants Participants with SP in the blood
N (%) N (%) 95% CI Bivariate analysis Multivariate analysis
ORs p-value ORs p-value
Total 6391 (100.0) 510 (8.0) 7.4–8.5 - -
Sex
Male 2802 (43.8) 200 (7.1) 6.3–7.9 0.97 0.036 - -
Female 3573 (55.9) 310 (8.7) 7.9–9.4
Missing 16 (0.3) - -
Age
0–4 years 1135 (17.8) 67 (5.9) 4.7–7.1 1.21 <0.001 1.18 <0.001
5–9 years 996(15.6) 43 (4.3) 3.3–5.4
10–14 years 765 (12.0) 41 (5.4) 4.0–6.7
15–24 years 973 (15.2) 83 (8.5) 7.1–10.0
25–44 years 1422 (22.2) 168 (11.8) 10.4–13.2
45–59 years 552 (8.6) 62 (11.2) 9.0–13.4
60–100 years 445 (7.0) 39 (8.8) 6.6–11.0
Missing 103 (1.6) - -
Pregnant
Yes 104 (1.6) 28 (26.9) 19.7–34.1 4.91 <0.001 4.60 <0.001
No 1569 (24.6) 166 (10.6) 9.3–19.9
Not applicable 4718 (73.8) - -
Had a fever in the previous 2 weeks
Yes 1021 (16.0) 127 (12.4) 10.7–14.1 1.58 <0.001 1.71 <0.001
No 5364 (83.9) 383 (7.1) 6.6–7.7
Missing 6 (0.1) - -
mRDT result
Positive 1117 (17.5) 26 (2.3) 1.6–3.1 0.26 <0.001 0.28 <0.001
Negative 5272 (82.5) 484 (9.2) 8.5–9.8
Missing 2 (0.0) - -
Net use
Yes 4180 (65.4) 356 (8.5) 7.8–9.2 1.07 0.541 - -
No 2211 (34.6) 154 (7.0) 6.1–7.9
Missing 0 (0.0) - -
IRS in the previous year
Yes 1073 (16.8) 82 (7.6) 6.3–9.0 0.44 <0.001 0.46 <0.001
No 5316 (83.2) 428 (8.0) 7.4–8.7
Missing 2 (0.0) - -
Area
Urban 2185 (34.2) 224 (10.2) 9.2–11.3 0.57 0.145 - -
Rural 4206 (65.8) 286 (6.8) 6.2–7.4
Missing 0 (0.0) - -
Region
Mbeya (reference) 1970 (30.8) 134 (6.8) 5.9–7.7
Mwanza 2304 (36.1) 281 (12.2) 11.1–13.3 1.59 0.241 3.92 <0.001
Mtwara 2117 (33.1) 95 (4.5) 3.7–5.2 0.56 0.156 1.02 0.942
Missing 0 (0.0) - -
PfPR2-10 of the ward
0 < 1% 1421 (22.2) 131 (9.2) 8.0–10.5 0.89 0.102 - -
(Continued)
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Table 2. (Continued)
Total participants Participants with SP in the blood
N (%) N (%) 95% CI Bivariate analysis Multivariate analysis
ORs p-value ORs p-value
1 - < 5% 0 (0.0) - -
5 - < 10% 1453 (22.7) 107 (7.4) 6.2–8.5
10 - < 50% 2062 (32.3) 169 (8.2) 7.2–9.2
> 50% 1455 (22.8) 103 (7.1) 6.0–8.2
Missing 0 (0.0) - -
PfPR2-10 of the district
0 < 1% 1244 (19.5) 96 (7.7) 6.5–9.0 0.73 0.044 0.77 0.010
1 - < 5% 0 (0.0) - -
5 - < 10% 1470 (23.0) 175 (11.9) 10.5–13.3
10 - < 50% 2259 (35.3) 191 (8.5) 7.5–9.4
> 50% 1418 (22.2) 48 (3.4) 2.6–4.2
Missing 0 (0.0) - - -
Time to the closest HF
<15 min 2134 (33.4) 194 (9.1) 8.1–10.1 0.83 0.003 0.85 0.031
15 min to 1h 3483 (54.5) 279 (8.0) 7.2–8.8
1h to 2h 564 (8.8) 27 (4.8) 3.3–6.3
> 2h 167 (2.6) 8 (4.8) 2.1–7.5
Don’t know 43 (0.7) - -
Time to the closest DS
<15 min 2911 (45.5) 264 (9.1) 8.2–10.0 0.89 0.105 - -
15 min to 1h 2599 (40.7) 200 (7.7) 6.8–8.6
1h to 2h 461 (7.2) 36 (7.8) 5.7–9.9
> 2h 63 (1.0) 3 (4.8) 0.3–9.2
Don’t know 357 (5.6) - -
ACTs in stocks in all the visited HF of the ward
Yes 6391 (100.0) 510 (8.0) 7.4–8.5 - - - -
No 0 (0.0) - -
Missing 0 (0.0) - -
AM in stocks in all the visited HF of the ward
Yes 6391 (100.0) 510 (8.0) 7.4–8.5 - - - -
No 0 (0.0) - -
Missing 0 (0.0) - -
mRDTs in stocks in all the visited HF of the ward
Yes 4986 (78.0) 454 (9.1) 8.4–9.8 1.48 0.238 - -
No 1405 (22.0) 56 (4.0) 3.1–4.8
Missing 0 (0.0) - -
ACTs in stocks in all the visited DS of the ward
Yes 5528 (86.5) 467 (8.4) 7.8–9.1 1.27 0.839 - -
No 399 (6.2) 17 (4.3) 2.6–5.9
Missing 464 (7.3) - -
AM in stocks in all the visited DS of the ward
Yes 5694 (89.1) 479 (8.4) 7.8–9.0 1.39 0.875 - -
No 233 (3.6) 5 (2.1) 0.6–3.7
Missing 464 (7.3) - -
mRDTs in stocks in all the visited DS of the ward
(Continued)
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(OR = 0.9, p<0.001) and living further away from a HF (OR = 0.8, p = 0.007) were associated
with lower odds of detecting LF/DLF. Having had a fever in the previous two weeks (OR = 2.6,
p<0.001), living in a district with higher malaria prevalence (OR = 1.5, p<0.001), sleeping
under a bed net (OR = 1.3, p = 0.004) and living in a ward in which all visited drug stores
(DSs) had ACTs in stocks (OR = 2.7, p = 0.020) were associated with higher odds of having
DLF/LF in the blood. When considering interactions in the model (S1 File), a statistically sig-
nificant interaction between age and mRDT result (p<0.001) was noted and showed that
increasing age was associated with lower odds of having LF/DLF in the blood only for the indi-
viduals tested positive by mRDT. A significant interaction between district parasite prevalence
and fever (p<0.001) also showed that the likelihood of having LF/DLF in the blood according
to fever was higher at low endemicity than at high endemicity.
Concerning the model for SP, being pregnant (OR = 4.6, p<0.001), living in Mwanza
(OR = 3.9, p<0.001 compared to Mbeya), having had a fever in the previous two weeks
Table 2. (Continued)
Total participants Participants with SP in the blood
N (%) N (%) 95% CI Bivariate analysis Multivariate analysis
ORs p-value ORs p-value
Yes 713 (11.2) 96 (13.5) 11.4–15.6 1.73 0.223 - -
No 5217 (81.6) 388 (7.4) 6.8–8.0
Missing 464 (7.3) - -
HF = Health Facility.
DS = Drug Store.
AM = antimalarial drug.
https://doi.org/10.1371/journal.pone.0202745.t002
Fig 1. Percentage of participants with residual antimalarial concentrations in each study region. LF, lumefantrine;
DLF, desbutyl-lumefantrine; SD, sulfadoxine; PM, pyrimethamine; MQ, mefloquine; Q, quinine; CQ, chloroquine;
AQ, amodiaquine; DAQ, N-desethyl-amodiaquine.
https://doi.org/10.1371/journal.pone.0202745.g001
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(OR = 1.7, p<0.001) and increasing age (OR = 1.2, p<0.001) were associated with higher odds
of having SP in the blood. Inversly, being tested positive by mRDT (OR = 0.3, p<0.001), living
in a house that had been sprayed by IRS in the previous year (OR = 0.5, p<0.001), living in a
district with higher malaria prevalence (OR = 0.8, p = 0.010) and living further from a HF
(OR = 0.8, p = 0.031) were associated with lower odds of having SP in the blood. Considering
the interaction between region and pregnancy (p = 0.002) showed that the likelihood of having
SP in the blood when pregnant was much higher in Mbeya and Mtwara than in Mwanza (S1
File). The significant interaction between region and time to the closest HF (p = 0.002)
revealed that individuals living further from a HF were less likely to have SP in their blood in
Mwanza only.
Discussion
Knowing how antimalarial medication circulates in the population and what the most impor-
tant drivers of antimalarial consumption are may help to improve treatment appropriateness
and prevent the emergence and spread of resistant parasites. To our knowledge, this is the first
study assessing drug consumption by means of antimalarial blood concentrations including
such a large sample size [19,20,25].
Overall, 20.8% of the study participants had antimalarials in the blood. LF/DLF composed
more than half (59.5%) of the drugs detected in our sampled population. Most of the factors
significantly associated with the presence of LF/DLF in the blood were expected, including his-
tory of fever, which had the highest ORs. Indeed, when fever occurs, antimalarials and antibi-
otics are commonly used as presumptive treatment [19,24], with or without parasitological
confirmation. However, odds of having LF/DLF in the blood according to fever were modu-
lated by district parasite prevalence and were found to be higher at low endemicity. This could
be explained by the fact that districts with highest malaria endemicity are also the most rural.
Shortage of drugs and long waiting time at HFs due to disease burden, long distance to HFs
and inability to pay for health care are factors discouraging people to seek treatment in case of
fever and which might not apply in urban districts where inhabitants are wealthier and access
to care is less of a concern [11,37,38]. The association between younger age and the presence
of LF/DF in the blood adds to previous studies reporting that small children are more likely to
be taken to the HF and being treated with ACTs [19,23,25,37,38]. The interaction between age
and mRDT result revealed that odds of having LF/DLF in the blood in case of positive mRDT
Table 3. Multivariate logistic regression models used in the present analysis.
LF/DLF Model SP Model
Outcome Presence of lumefantrine and/or desbutyl-lumefantrine in the blood Presence of sulfadoxine and/or pyrimethamine in the blood
Regions All All
Number of
observations
6279 6278
Variables
Included Age; fever in the previous 2 weeks; mRDT result; net use; PfPr of the
district; time to the closest HF; ACTs in stocks in DS
Age, pregnant, fever in the previous 2 weeks, mRDT result, IRS in the
previous year, region, time to the closest HF
Excluded Sex; pregnant; IRS in the previous year; area; region; PfPr of the ward;
time to the closest DS; ACTs, AM, mRDTs in stocks in HF; AM, mRDTs
in stocks in DS
Sex; net use; area; PfPr of the district and of the ward; time to the
closest DS; ACTs, AM, mRDTs in stocks in HF; AM, ACTs, mRDTs in
stocks in DS
Nested random
effects
Regions/districts/wards Regions/districts/wards
Interaction terms
included
AgemRDT result; PfPr of the district fever in the previous 2 weeks Region pregnant; Regiontime to the closest HF
https://doi.org/10.1371/journal.pone.0202745.t003
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Fig 2. Multivariate analysis of the determinants for the presence of LF/DLF (A) and SP (B) in the blood of the
surveyed individuals. Lines width corresponds to 95% CI bounds and the number above each line correspond to the
association’s OR.  indicate the strength of the significance (levels of significance:  = p<0.05,  = p<0.01,  =
p<0.001) obtained from the multivariate analysis.
https://doi.org/10.1371/journal.pone.0202745.g002
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decreased when age increased. This supports previous observations that children are better
cared than older people, which is encouraging since children are the most vulnerable popula-
tion [39]. The effect of the distance to HF and drug stocks in DSs on the presence of LF/DLF
confirms that access to treatment (including distance to health care provider and treatment
availability) leads to more drug consumption, and hence drug pressure [10,19,40]. In our data,
distance to DS did not play a role on pattern of drug use, probably because all households were
located within a short radius of DSs. Such leveling effect has previously been reported in the lit-
erature [10]. We could not detect an effect of drugs availability in HFs on antimalarial use
since all HFs visited during the survey had ACTs in stock. However, the significant effect of
stocks of ACTs in DSs shows the importance of these providers, as often reported in the litera-
ture [29,41].
SP accounted for 38.3% of all antimalarials detected although it has been shown to have low
therapeutic value in Tanzania [4,9], and that SP super-resistant haplotypes are widespread
throughout the country [8]. SP had been officially abandoned as first line treatment in 2006 in
Tanzania [4] but is still present in HFs for IPTp [4]. Amongst all individuals, 8.0% (510/6391)
had SP in the blood. According to 2015–16 DHS surveys [42], 8.6% of women aged between
15–49 years are pregnant on average. Considering that women aged between 15–49 years rep-
resent around 25.0% of the total population [43], one would expect around 2.0% of the partici-
pants to have SP in their blood, much lower than the proportion measured in our study. As
mentioned before, this large discrepancy goes in line with previous studies reporting the com-
mon use of SP as self-medication [11,22,44]. Measuring SP in the blood provides interesting
insight on how these treatments are used in different regions of the country and by different
population groups. For example, in the univariate analysis, female were more likely to have SP
in the blood. However, this association was no longer significant when adjusting for pregnancy
in the multivariate analysis as previously reported in the literature [19,20,23,28]. Indeed, it was
pregnancy that was a strong predictor of the presence of SP in the blood, which reflects adher-
ence to IPTp programs [4]. This association was nevertheless mitigated in Mwanza, the reason
possibly being that in Mbeya and Mtwara the use of SP is more restricted to IPTp while in
Mwanza, treating malaria with SP is more common practice. This hypothesis is reinforced by
the fact that Mwanza was the region with the highest proportion of individuals with SP in the
blood, and the only region for which distance to HF had significant influence on the presence
of SP in the blood. Age was also significantly associated with the presence of SP in the blood
but contrary to DLF/LF, residual levels of SP were more likely to occur in older people, who
have more often recourse to self-medication [45]. These results tend to show that compliance
to standard malaria treatment recommendations is lower in Mwanza and in adults.
Almost all antimalarials detected in the studied population were part of the recommended
treatments in Tanzania, which is encouraging. Beside LF/DLF and SP, which were the most
prevalent, 123 individuals (9.3% of all antimalarials detected) were found with quinine, meflo-
quine, amodiaquine or its metabolite N-desethyl-amodiaquine (which were more prevalent
due to amodiaquine’s short half-life of 3.9h when used in ACTs [46]). Quinine is the drug of
choice for treatment of severe malaria and second line drug in case of treatment failure with
Alu. Amodiaquine and mefloquine can both be found Tanzania in combination with artesu-
nate as a viable option for treating uncomplicated malaria [4]. Three individuals had chloro-
quine in their blood although it had been banned from the therapeutic armamentarium in
2001.
Previous studies conducted in Tanzania reported that around 2.0% of the fever in low and
8–20% in highly endemic settings ([47–49] Boillat et al, unpublished) are due to malaria. In
our study, 1021 individuals reported a fever in the previous two weeks (Tables 1 and 2), and
630 of them said they sought care because of their fever [29]. Considering that, on average,
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10.0% of fevers are due to malaria according to literature, 63 individuals should have received
an antimalarial. This number can be doubled because LF can be detected in DBS samples for
up to one month (unpublished data) and history of fever recall was based on a two-week
period. These estimations should have resulted in a prevalence of 19.7% (1260/6391) of the
total surveyed population (providing all participants who sought care in the previous month
were treated) having LF detected in their blood if none had a diagnostic test done and 2.0%
(126/6391) if all had been tested and treated upon result. Together with the 2.0% of the pop-
ulation constituted by pregnant women receiving SP through IPTp, we would expect 4.0% of
the participants to have an antimalarial in the blood, which is far from what we measured
(20.8%). This highlights the urgent need to implement interventions aimed at decreasing drug
pressure, notably encourage the use of mRDTs to target treatments to individuals with malaria
only.
Our study’s main limitation resides in the fact that we did not collect all possible informa-
tion on potential factors influencing drug use. Socio-economic determinants, knowledge and
attitude on malaria management might have been of interest, although differences in wealth
might not have been much different, at least in rural areas.
Conclusion
Understanding pattern of antimalarial drug use has implication in malaria control (access to
care as well as diagnostic and treatment policies implementation) and surveillance (parasite
resistance). The most significant predictors identified were encouraging since they implied
that people took a drug when they had a fever and that children were treated with standard
first line treatment, i.e. artemether-lumefantrine. However, the long-standing belief that access
to treatment should be increased might need to be revisited [50], as proven by the number of
people having drugs in their blood and the good availability of drugs in the health facilities and
drug stores. Efforts need rather to be focused on the appropriate use of these drugs, namely to
target antimalarial treatment to those who have malaria, with the appropriate dosage and cor-
rect adherence, and to recommend the use first-line efficacious drugs in adults [51]. This study
has shown that drug pressure was highest in districts of high transmission and in most accessi-
ble locations. This observation calls for interventions to be targeted to such areas since they
constitute favorable conditions for development and spread of resistant strains.
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